Literature DB >> 31736201

Omic approaches to pediatric bone sarcomas.

Elisa Tirtei1, Matteo Cereda2,3, Elvira De Luna1, Paola Quarello1, Sebastian Dorin Asaftei1, Franca Fagioli1,4.   

Abstract

Over the last decade, next-generation sequencing technologies have improved our ability to assess biological aspects, at genomic and transcriptomic levels, on a large scale- and have been increasingly used for the management of adult cancers. However, their efficacy and feasibility within pediatrics is still under investigation. "Omic" approaches represent an opportunity to understand the oncogenic mechanisms driving the onset and progression of bone sarcoma and improve the clinical management of young patients with bone sarcomas. This review focuses on the current genomic and transcriptomic characteristics of managing pediatric patients, affected by Ewing sarcoma and osteosarcoma.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ewing sarcoma; genomic; next-generation sequencing; osteosarcoma; pediatric oncology; transcriptomic

Year:  2019        PMID: 31736201     DOI: 10.1002/pbc.28072

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  3 in total

Review 1.  Artificial Intelligence in Bulk and Single-Cell RNA-Sequencing Data to Foster Precision Oncology.

Authors:  Marco Del Giudice; Serena Peirone; Sarah Perrone; Francesca Priante; Fabiola Varese; Elisa Tirtei; Franca Fagioli; Matteo Cereda
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 2.  Precision Medicine in Osteosarcoma: MATCH Trial and Beyond.

Authors:  Elisa Tirtei; Anna Campello; Sebastian D Asaftei; Katia Mareschi; Matteo Cereda; Franca Fagioli
Journal:  Cells       Date:  2021-01-31       Impact factor: 6.600

3.  Mutational landscape of primary and recurrent Ewing sarcoma.

Authors:  Paulina Jagodzińska-Mucha; Paweł Sobczuk; Michał Mikuła; Anna Raciborska; Anna Dawidowska; Maria Kulecka; Katarzyna Bilska; Anna Szumera-Ciećkiewicz; Anna Kluska; Magdalena Piątkowska; Anna Bałabas; Piotr Rutkowski; Iwona Ługowska
Journal:  Contemp Oncol (Pozn)       Date:  2021-12-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.